Sorrento Therapeutics Inc (SRNE)
0.02
0.00 (0.00%)
USD |
OTCM |
Apr 24, 16:00
Sorrento Therapeutics Cash from Financing (TTM): 246.59M for June 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
June 30, 2023 | 246.59M |
March 31, 2023 | 199.54M |
December 31, 2022 | 311.72M |
September 30, 2022 | 357.50M |
June 30, 2022 | 326.06M |
March 31, 2022 | 319.34M |
December 31, 2021 | 181.33M |
September 30, 2021 | 98.90M |
June 30, 2021 | 176.69M |
March 31, 2021 | 184.87M |
December 31, 2020 | 174.24M |
September 30, 2020 | 223.72M |
June 30, 2020 | 128.44M |
March 31, 2020 | 104.70M |
December 31, 2019 | 78.88M |
September 30, 2019 | 124.27M |
June 30, 2019 | 269.00M |
March 31, 2019 | 296.67M |
December 31, 2018 | 326.00M |
September 30, 2018 | 271.22M |
June 30, 2018 | 105.96M |
March 31, 2018 | 104.39M |
December 31, 2017 | 53.68M |
September 30, 2017 | 70.29M |
June 30, 2017 | 61.12M |
Date | Value |
---|---|
March 31, 2017 | 106.70M |
December 31, 2016 | 131.74M |
September 30, 2016 | 84.50M |
June 30, 2016 | 91.04M |
March 31, 2016 | -0.079M |
December 31, 2015 | -3.347M |
September 30, 2015 | 44.21M |
June 30, 2015 | 44.74M |
March 31, 2015 | 71.38M |
December 31, 2014 | 79.59M |
September 30, 2014 | 66.35M |
June 30, 2014 | 70.58M |
March 31, 2014 | 43.83M |
December 31, 2013 | 43.57M |
September 30, 2013 | 11.39M |
June 30, 2013 | 7.220M |
March 31, 2013 | 13.21M |
December 31, 2012 | 5.97M |
September 30, 2012 | 7.914M |
June 30, 2012 | 7.914M |
March 31, 2012 | 1.984M |
December 31, 2011 | 1.984M |
September 30, 2011 | 3.448M |
June 30, 2011 | 3.448M |
March 31, 2011 | 3.440M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
78.88M
Minimum
Dec 2019
357.50M
Maximum
Sep 2022
206.22M
Average
184.87M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
Scilex Holding Co | 23.58M |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Armata Pharmaceuticals Inc | 53.99M |